Open AccessSERUM LIPIDS AND LIPOPROTEINS IN PATIENTS WITH ENDOMETRIAL CARCINOMA RECEIVING ADJUVANT TREATMENT WITH HYDROXYPROGESTERONE CAPROATE
Author(s) -
Onsrud Mathias
Publication year - 1985
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016348509154714
Subject(s) - medicine , progestogen , cholesterol , carcinoma , endocrinology , gastroenterology , hydroxyprogesterone , adjuvant , endometrial cancer , hormone , cancer , steroid
. Serum levels of triglycerides, total cholesterol, and HDL‐cholesterol were determined in 57 patients who were undergoing treatment for stage 1 endometrial carcinoma. The patients belonged to a clinical trial where group A (control) was treated with surgery plus intravaginal irradiation, whereas group B in addition was treated with hy‐droxyprogesterone caproate (5000 mg i.m. as a loading dose followed by 1000 mg every 2 weeks for one year). In group B patients followed during the first 13 weeks of treatment, the level of serum triglycerides remained stable, whereas the level of total cholesterol and HDL‐cholesterol increased significantly. This increase could not, however, have been caused by the progestogen treatment, as similar changes were seen in group A patients followed for the same period of time. Long‐term effects were looked for in patient groups examined 3‐12 months after the start of treatment and in groups examined 3—6 months after the hormone therapy was stopped. In neither group could any significant difference in cholesterol or HDL‐cholesterol be found. It is concluded that this type of progestogen treatment causes no significant change in the levels of triglycerides, cholesterol, and HDL‐cholesterol.